2 results
Approved WMOCompleted
Part A: Determine safety and tolerability of FTX-1821 in healthy subjects. Part B and C: Determine safety and tolerability of FTX-1821 in FSHD patients.
Approved WMOCompleted
Objectives of part A:- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after 5 days of dosing in people with Parkinson's disease- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after…